8 years ago

Bicycle Therapeutics Raises £40 Million in Series B Funding

  • Bicycle Therapeutics, a Cambridge, UK-based biotechnology company, has secured £40 million in Series B funding

  • The round was led by Vertex Ventures HC, with participation from Cambridge Innovation Capital (CIC), Longwood Fund, Novartis Venture Fund, SROne, SVLS, and Atlas Venture

  • The company plans to utilize the funds to advance the development of multiple drug candidates, including its lead molecule, BT1718, and other pipeline programs through early clinical development

  • Bicycle Therapeutics is developing novel medicines that combine the properties of antibodies, small molecules, and peptides

  • Its lead molecule, BT1718, is the first example of its Bicycle Drug Conjugate® (BDC) technology, which targets malignant tumors specifically, minimizing systemic toxin exposure

  • BT1718 is expected to enter the clinic in 2017 in partnership with Cancer Research UK (CRUK).

      • ProblemHealthcare

      "Cancer is a devastating disease with limited treatment options. Many current therapies have significant side effects, and drug resistance is a common problem. "

      Solution

      "Bicycle Therapeutics is developing a new class of drugs called Bicycles® which are designed to target cancer cells specifically, reducing side effects and overcoming drug resistance. Bicycles® combine the best features of antibodies, small molecules, and peptides, making them a promising new approach to cancer treatment. "

      Covered on